Tower Research Capital LLC (Trc) Tyme Technologies, Inc. Transaction History

Tower Research Capital LLC (Trc)

$5.8 Billion
Q2 2024

Shares

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2022 Aug 15, 2022	BUY	$0.23 - $0.35 $3,643 - $5,545	15,843 Added 279.81%	21,505 $6,000
Q1 2022 May 12, 2022	BUY	$0.28 - $0.68 $1,585 - $3,850	5,662 New	5,662 $2,000
Q4 2021 Feb 14, 2022	SELL	$0.6 - $1.04 $4,521 - $7,837	-7,536 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$0.99 - $1.38 $21,499 - $29,969	-21,717 Reduced 74.24%	7,536 $8,000
Q2 2021 Aug 16, 2021	SELL	$1.14 - $1.87 $2,706 - $4,439	-2,374 Reduced 7.51%	29,253 $37,000
Q1 2021 May 17, 2021	BUY	$1.34 - $3.53 $4,223 - $11,126	3,152 Added 11.07%	31,627 $56,000
Q4 2020 Feb 16, 2021	SELL	$0.87 - $1.26 $39,684 - $57,473	-45,614 Reduced 61.57%	28,475 $35,000
Q3 2020 Nov 16, 2020	BUY	$0.93 - $1.35 $47,413 - $68,825	50,982 Added 220.63%	74,089 $73,000
Q2 2020 Aug 13, 2020	BUY	$0.97 - $1.7 $21,289 - $37,311	21,948 Added 1893.7%	23,107 $31,000
Q1 2020 May 15, 2020	BUY	$0.9 - $1.95 $1,043 - $2,260	1,159 New	1,159 $1,000
Q3 2018 Nov 13, 2018	SELL	$2.18 - $3.44 $20,696 - $32,659	-9,494 Closed	0 $0
Q2 2018 Aug 15, 2018	BUY	$2.05 - $4.09 $19,462 - $38,830	9,494 New	9,494 $30,000

About TYME TECHNOLOGIES, INC.

Ticker TYME
Exchange NASDAQ
Shares Outstandng 172,207,008
Description
Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead drug product is SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. The company is also devel...

More about TYME

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.